文献类型：期刊文献

英文题名：Synergistic osteogenesis and angiogenesis in promoting bone repair by levistolide A-induced smad pathway activation

作者：Han, Zhengzhe[1];Li, Ang[1];Yu, Yuanman[2];Dai, Kai[2];Yin, Wenjing[1];Li, Xiaolin[1];Wang, Jing[2];Yu, Min[3];Qi, Xin[1];Li, Qi[1]

机构：[1]Shanghai Jiao Tong Univ, Shanghai Inst Microsurg Extrem, Dept Orthoped, Shanghai Peoples Hosp 6,Sch Med, Shanghai 200233, Peoples R China;[2]East China Univ Sci & Technol, Key Lab Ultrafine Mat Minist Educ, Shanghai 200237, Peoples R China;[3]Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai, Peoples R China

年份：2024

卷号：275

外文期刊名：COMPOSITES PART B-ENGINEERING

收录：;EI(收录号：20241015706187);WOS:【SCI-EXPANDED(收录号:WOS:001205786000001)】；

基金：This work was financially supported by National Natural Science Foundation of China (81702137, 82202695, 82072422) , Three-year Action Plan of Shanghai Municipality for Further Accelerating the Inheritance, Innovation and Development of Traditional Chinese Medicine: Shanghai High Level Talent Guiding Project in Traditional Chinese Medicine [grant number: ZY(2021-2023)-0403] , Shanghai Municipal Health Commission Scientific Research project plan [grant number: 202340059] , Collaborative Traditional Chinese Medicine and Western Medicine Guiding Project of General Hospital [grant number: ZXXT-202308] , 2nd national Western medicine doctor studying TCM excellent talents research plan (2023.6-2026.5) , and the Special Project of Clinical Research for Health Industry from Shanghai Health Committee (Grant No. 20214Y0323) .

语种：英文

外文关键词：Bone defects; Levistolide a; Osteogenesis; Angiogenesis

摘要：Bone defects are a prevalent issue in orthopedics clinics, and tissue engineering offers a new hope for treatment. Angiogenesis ability is indispensable during the healing process of bone defects, and the combination of osteogenesis and angiogenesis ability is essential in treating bone defects effectively. Herein, with the aid of traditional Chinese medicine, we have discovered that Levistolide A, a component of Angelica sinensis, has the potential in treating bone defects due to its angiogenesis ability. In vitro experiments have demonstrated its ability to promote the proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells. Levistolide A can also indirectly promote the proliferation and recruitment of endothelial cells. Our proteomics analysis revealed that Levistolide A inhibited skp-1 and activated the Smad pathway to exert its effect on bone marrow mesenchymal stem cells. In vivo experiments proved that combined with a bioactive material scaffold, Levistolide A is used to effectively repair rat skull defects. Based on the above results, we have discovered a small molecule, which is cheap and stable. It can also provide hope for treatment of a large number of clinical patients.